CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

Digitization in Mecklenburg-Vorpommern

As part of an exchange with senior business and academic leaders, and state of Mecklenburg-Vorpommern (M-V) government representatives, a discussion…

Read more

CENTOGENE Announces Strategic Collaboration with Sarepta Therapeutics

Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)

Read more

New Validation Framework to Optimize Specificity and Sensitivity in WES-Based Diagnostics

CENTOGENE, a rare disease company committed to improving the lives of rare disease patients by providing solutions that accelerate the development of…

Read more

CENTOGENE Expands Clinical Studies Team in U.S.

Driving Pharmaceutical Partnerships and Accelerating Orphan Drug Development

Read more

CENTOGENE Receives Prestigious Re-Accreditation by College of American Pathologists

CENTOGENE’s state-of-the-art genetic laboratory facilities in Rostock, Germany awarded accreditation for the fourth year

Read more

CENTOGENE Corporate and Business Unit Update 2018

2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of diagnostic testing portfolio for rare…

Read more

CENTOGENE and Chiesi Germany sign a strategic alliance in lysosomal storage disorders

CENTOGENE to perform epidemiology study in Alpha Mannosidosis to support Chiesi’s drug discovery and development

Read more

CENTOGENE earns Accreditation to ISO 15189:2012 from CAP

The College of American Pathologists (CAP), a Center for Medicare and Medicaid Services (CMS)-approved accreditation authority, has awarded CENTOGENE…

Read more

Updates to CentoMD®, World’s Largest Genetic Mutation Database of Rare Diseases

Provides physicians with virtual encyclopedia of genetic information at their fingertips for improved and efficient diagnosis of rare diseases

Read more

CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials

CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2…

Read more

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads